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Restriction of HIV-1-based lentiviral 
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prior to viral DNA integration
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Abstract 
Background: Gene therapy is currently being attempted using a number of delivery vehicles including lentiviral-
based vectors. The delivery and insertion of a gene using lentiviral-based vectors involves multiple discrete steps, 
including reverse transcription of viral RNA into DNA, nuclear entry, integration of viral DNA into the host genome 
and expression of integrated genes. Transduction of murine stem cells by the murine leukemia viruses is inefficient 
because the expression of the integrated DNA is profoundly blocked. Transduction of human stem cells by lentivirus 
vectors is also inefficient, but the cause and specific part of the retroviral lifecycle where this block occurs is unknown.
Results: Here we demonstrate that the dominant point of restriction of an HIV-1-based lentiviral vector in adult 
human hematopoietic stem and progenitor cells (HSPCs) from bone marrow and also those obtained following 
peripheral mobilization is prior to viral DNA integration. We specifically show that restriction of HSPCs to an HIV-1-
based lentiviral vector is prior to formation of nuclear DNA forms.
Conclusions: Murine restriction of MLV and human cellular restriction of HIV-1 are fundamentally different. While 
murine restriction of MLV occurs post integration, human restriction of HIV-1 occurs before integration.
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Background
Gene therapy, the ability to replace an abnormal gene 
with a functionally correct copy or to introduce a novel 
gene for therapeutic purposes, holds great potential for 
the improvement of human health [1]. Safe and effective 
gene therapy is being pursued through careful selection 
of viruses as delivery vehicles and genetic modifications 
of the original virus [2]. Gene therapy is currently in pro-
gress with success in a number of patients with a range 
of genetic disorders such as immunodeficiency due to 
adenosine deaminase deficiency [3], Wiskott–Aldrich 
syndrome [4], metachromic leukodystrophy [5], X-linked 
severe combined immunodeficiency [6], β-thalassemia 
[7], sickle cell anemia [8, 9] and X-linked adrenoleukod-
ystrophy [10]. Gene therapy trials are currently ongoing 
for many other intractable genetic diseases as well as 
malignancies, arthritis, congestive heart failure, Parkin-
son’s disease, Alzheimer’s disease and macular degenera-
tion [8].
Despite the ability of lentiviruses to successfully infect 
non-dividing cells, HIV-1 infection of human hemat-
opoietic stem cell and progenitor cells (HSPCs) is ineffi-
cient as compared to activated T cells unless HSPCs are 
prestimulated [2, 11–13]. An augmentation of successful 
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lentiviral infection of human HSPCs is seen with high 
multiplicity of infection (MOI) exposures and treat-
ment of human stem cells with multiple cytokines such 
as interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-7 
(IL-7), stem cell factor (SCF), Flt3 ligand (FLT3L), and 
thrombopoietin (TPO), with proteasome inhibitors, with 
targeted siRNA blockade of the cell cycle quiescent factor 
p21, or with cyclophilin A, rapamycin and cyclosporine 
[4, 5, 8, 14–21]. Unfortunately, exposure of HSPCs to 
combinations of cytokines prior to exposure to lentivirus 
at a high (MOI) decreases the multipotency of HSPCs 
as evidenced by diminished engraftment potential in 
murine models [18].
Some investigations suggest the innate response and a 
type I interferon response may be instrumental in restric-
tion of lentiviruses in certain cell types [22–24]. Other 
investigations have suggested a limited role of interferon-
stimulated genes in the restriction of HIV-1 and related 
vectors in the human system [25, 26]. It is also unclear 
whether the restriction of lentiviruses in HSPCs is due to 
a specific restriction factor such as TRIM5α, as has been 
found in other cell types, or to the absence of a specific 
essential co-factor of infection [27–29]. When human 
HSPCs are pre-stimulated with cytokines a large number 
of genome-wide modifications occur that allow for suc-
cessful lentiviral transduction, but the essential changes 
responsible for this transformation remain unexplored 
[30].
Although several interventions increase the efficiency 
of lentiviral transduction, the point in the retroviral rep-
lication cycle at which retroviruses are blocked in adult 
human HSPCs remains unknown. Whether this involves 
a pre-integration block or is due to transcriptional silenc-
ing of integrated proviruses has not been studied in detail 
and is critical in determining whether murine mod-
els and results can be extrapolated to human cells [27, 
31–34]. An understanding of the molecular mechanisms 
used in restriction by HPSCs may allow us to successfully 
transduce human HPSCs without decreasing their pluri-
potency, diminishing their repopulating potential or their 
ability to engraft [35]. We sought to identify the specific 
point in the retroviral cycle where restriction occurs as a 
first and important step in understanding the molecular 
basis of this restriction. Our study evaluates infection of 
primary adult marrow-derived and peripheral mobilized 
human CD34+ cells, a mixed population composed of 
true human HSCs (Lin−34+38−90+45RAdim) as well as 
several hematopoietic progenitor cell (HPC) types, with 
a VSV-G pseudotyped full-length nef-negative HIV-1-
based vector.
Results
Transduction of primary adult human marrow‑derived 
CD34+ cells by lentiviral vectors is inefficient at low MOI
We investigated the efficiency of lentiviral transduc-
tion of primary adult human marrow-derived CD34+ 
cells under various conditions. We performed each 
experimental replicate independently with primary adult 
human marrow-derived CD34+ cells from multiple dif-
ferent donors. CD34+ cells were cultured in serum free 
VIVO-X 20 media. The cells were pre-incubated for 
24  h with no cytokines, FLT3L, SCF, TPO, or all three 
cytokines (“FST” cocktail). Cells were then exposed to 
vector virus by spinoculation, left in culture with virus 
for 72 h at 37°, and evaluated using flow cytometry.
Less than 1  % of marrow-derived CD34+ cells 
expressed ZsGreen when incubated in the absence of 
cytokines and exposed to pseudotyped virus at a MOI of 
1 based on titer in permissive 293T cells (Fig.  1). GFP-
positive cells only increased to 1–3 % following pre-stim-
ulation with cytokines individually or in combination. In 
contrast, the permissive 293T cells were efficiently trans-
duced under these conditions, with a large fraction of the 
population expressing ZsGreen (Fig. 1). A major block to 
transduction in primary adult human marrow-derived 
stem cells with or without cytokine stimulation was indi-
cated by these results (p < 0.005 for FST cells compared 
to 293T cells).
Transduction of primary adult human marrow‑derived 
CD34+ cells by lentiviral vectors is modestly increased 
by infection at high MOI
We exposed primary marrow-derived CD34+ cells and 
293T cells to pseudotyped virus at a calculated MOI of 10. 
We observed a modest increase in the transduction effi-
ciency of CD34+ cells under these conditions of high mul-
tiplicity with the addition of cytokines. While only 1–2 % of 
the cells expressed ZsGreen after 72 h without cytokines, 
2–16 % of the primary CD34+ cells expressed ZsGreen fol-
lowing the addition of various cytokines (Fig. 1). The vast 
majority of permissive 293T cells were efficiently trans-
duced under these conditions and expressed ZsGreen. 
Thus, exposure of the marrow-derived HSPCs to high 
concentrations of virus resulted in modest increases in the 
efficiencies of transduction when augmented by cytokine 
stimulation, particularly in the presence of a cytokine cock-
tail, but were still significantly decreased compared to 293T 
cells (p < 0.005 for FST cells compared to 293T cells). These 
conditions of increased MOI and prestimulation with a 
cytokine cocktail are similar to those used in many clinical 
gene therapy protocols [3–5, 7].
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Transduction of primary adult human peripheral mobilized 
CD34+ cells by lentiviral vectors is inefficient
Primary adult human peripheral mobilized CD34+ cells, 
in distinction from bone marrow-derived cells, were next 
used to study the efficiency of lentiviral transduction 
under various conditions. When adult human peripheral 
mobilized CD34+ cells were incubated in the absence or 
presence of cytokines individually or in combination, and 
exposed to pseudotyped virus at a MOI of 1, only about 1 % 
or less of these cells expressed ZsGreen (Fig. 2). In contrast, 
the permissive 293T cells were efficiently transduced under 
these conditions (Fig.  2) (p  <  0.05 for FST compared to 
293T). Thus, as in marrow-derived cells, there is a major 
block to transduction in primary adult human peripheral 
mobilized stem cells with or without cytokine stimulation. 
Under conditions of higher multiplicity (MOI of 10), we 
observed a modest increase in the transduction efficiency 
of CD34+ cells to roughly 2–4 % positive cells (Fig. 2). Per-
missive 293T cells again were efficiently transduced under 
these conditions (p < 0.005 for FST compared to 293T).
a b
c d
Fig. 1 Variable percentages of adult human marrow-derived CD34+ cells express ZsGreen after exposure to pseudotyped HIV-1 vector at relative 
MOI of 1 in the absence and with incubation with cytokines. Primary human CD34+ cells were incubated with no cytokines (no cyt), Flt3 ligand 
(FLT3L), stem cell factor (SCF), Thrombopoietin (TPO), all three cytokines (FST) or virus with nevirapine (NVP). 293T cells were similarly incubated 
with virus (293T + V) or virus plus nevirapine (293 + V + NVP). a Cells were evaluated by flow cytometry for expression of ZsGreen after 72 h and a 
representative example for each condition is shown for viral infection at a MOI of 1. b Percent CD34+ cells and 293T expressing ZsGreen with mean 
values and error bars indicating SEM (n = 3) for samples incubated with viral MOI of 1. c A representative example for CD34+ cells incubated in each 
condition is shown for viral MOI of 10. d Percent CD34+ cells and 293T cells expressing ZsGreen with mean values and error bars indicating SEM 
(n = 3) for samples incubated with virus at MOI of 10
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Intracellular lentiviral DNA forms in primary adult human 
marrow‑derived CD34+ cells exposed to pseudotyped 
virus at MOI of 1
The efficiency of various steps in the course of infec-
tion of adult marrow-derived CD34+ cells relative to 
the efficiency in permissive 293T cells was evaluated 
using qPCR with established PCR primer sequences, 
and using the chromosomal RNase-P gene as our Ref. 
[36]. Levels of total viral DNA, 2-LTR circular DNA, 
and integrated DNA were evaluated at 12, 24, 48 and 
72 h time points (Fig. 3). The DNA copy numbers were 
calculated relative to the copy number of the RNase-P 
gene. Infection of the marrow-derived CD34+ cells at 
an MOI of 1 produced peak levels of total viral DNA in 
the range of 0.5–1.2 copies relative to the single copy 
gene, with only minimal change upon incubation with 
cytokines. Infection of the permissive 293T cells under 
these conditions yielded a peak mean level of 1.46 
a b
dc
Fig. 2 Variable percentages of adult human marrow-derived CD34+ cells express ZsGreen after exposure to pseudotyped HIV-1 vector at relative 
MOI of 10 in the absence and with incubation with cytokines. Primary human CD34+ cells were incubated with no cytokines (no cyt), Flt3 ligand 
(FLT3L), stem cell factor (SCF), Thrombopoietin (TPO), all three cytokines (FST) or virus with nevirapine (NVP). 293T cells were similarly incubated 
with virus (293T + V) or virus plus nevirapine (293 + V + NVP). a Cells were evaluated by flow cytometry for expression of ZsGreen after 72 h and a 
representative example for each condition is shown for viral MOI of 1. b Percent CD34+ cells and 293T cells expressing ZsGreen with mean values 
and error bars indicating SEM (n = 3) for samples incubated with viral MOI of 1. c A representative example for CD34+ cells incubated in each con-
dition is shown for viral MOI of 10. d Percent CD34+ cells and 293T cells expressing ZsGreen with mean values and error bars indicating SEM (n = 3) 
for samples incubated with virus at MOI of 10
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copies of total viral DNA per single copy gene (Fig. 3a). 
Thus, the efficiency of total viral DNA synthesis in 
CD34+ cells at all time points was almost as high as 
that seen in permissive cells. Tests of infections carried 
out in the presence of the RT inhibitor NVP revealed 
undetectable levels of viral DNA, confirming that the 
DNA being detected was due to true infection and was 
not attributable to contaminating plasmid DNA pre-
sent in the virus preparations. There was apparently no 
significant block to entry into these cells for virus using 
the VSV G envelope.
Analysis of circular viral DNAs containing the 2-LTR 
junction sequence revealed only extremely low levels 
of DNA in the marrow-derived CD34+ cells (Fig.  3a). 
Infection at an MOI of 1 produced peak mean levels of 
2-LTR circles, relative to the single copy gene, of 0.002 
copies with no cytokines, 0.02 with FLT3L, 0.08 cop-
ies with SCF, 0.001 copies with TPO, and 0.05 copies 
* * * * * * * * *
* * * * * * * * *
a
b
Fig. 3 The kinetics of production of total viral DNA, 2-LTR circles, and integrated DNAs in adult human bone marrow derived CD34+ cells after 
exposure to pseudotyped HIV-1 vector at MOI of 1 and 10. Primary human CD34+ cells were incubated with either nevirapine (NVP) or with no 
cytokines (no cyt), Flt3 ligand (FLT3L), stem cell factor (SCF), Thrombopoietin (TPO), or all three cytokines (FST). 293T cells were similarly infected as 
a permissive cell control (293T). a Cells were lysed at 12, 24, or 48 h, after infection at MOI of 1, and DNA was extracted and analyzed by taqman PCR 
analysis for products relative to RNase-P (n = 3 per condition and per time point). DNA levels relative to RNase-P with bars representing mean and 
error bars indicating SEM. b Cells were analyzed at 12, 24, 48 and 72 h after infection at MOI of 10. Results are shown relative to RNase-P with bars 
representing mean and error bars indicating SEM. Asterisk indicates undetectable levels with NVP after amplification for 50 cycles
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with all 3 cytokines combined. The levels in the permis-
sive 293T cells were dramatically higher, at 0.7 copies 
per single copy standard (p  =  0.008 for CD34+ cells 
relative to 293T cells at 72 h). Across the various condi-
tions, the 2-LTR circular DNAs levels on average were 
approximately 20 fold lower than the total viral DNA in 
CD34+ cells, while the circles were only approximately 
twofold lower than total viral DNA in permissive cells 
(p = 0.0001 for CD34+ cells peak total DNA versus peak 
2-LTR DNA). These resulted were indicative of a strong 
block in infection of marrow derived CD34+ cells, likely 
at the stage of nuclear entry.
Analysis of the copy numbers of the integrated proviral 
DNA in the CD34+ cells revealed a similar reduction as 
was seen for 2-LTR circles when compared to 293T cells 
(Fig. 3a). We assessed integration using a taqman-based 
assay, scoring for linkage between host Alu repeats and 
the vector LTR sequences (Alu-LTR levels). We could not 
detect any amplified products in the CD34+ cells after 
50 cycles of PCR in the cells not exposed to cytokines. 
With addition of FLT3L, SCF, TPO, or all three combined 
(FST), the levels peaked at 0.013–0.13 DNA copies com-
pared to the single-copy standard. The permissive cells 
yielded approximately 0.48 DNA copies relative to the 
single-copy gene standard. Thus, although substantial 
levels of viral DNA were synthesized in the CD34+ cells, 
very little DNA entered the nucleus to form 2-LTR circles 
or proviral DNAs.
To confirm our ability to quantify integrated viral 
DNAs, We performed Alu-LTR PCR on HeLa cell lines 
transduced at very low MOI and sorted for reporter gene 
expression, and so carrying single proviruses as controls. 
We consistently obtained copy numbers of approxi-
mately 0.5 relative to RNase-P (in good agreement with 
expectation).
Circular and integrated lentiviral DNA forms are 
also profoundly reduced in primary adult human 
marrow‑derived CD34+ cells exposed to pseudotyped 
virus at MOI of 10
To explore the simplest approach to increasing transduc-
tion of the human CD34+ cells, we repeated the chal-
lenges with higher multiplicities of virus. Adult human 
marrow-derived CD34+ cells and control permis-
sive 293T cells were exposed to pseudotyped virus at a 
MOI of 10, with and without cytokines, and DNA was 
extracted at various times post-infection and analyzed 
by PCR as before. Infection at these high MOIs resulted 
in substantial increases in the level of total viral DNA 
over that seen at lower MOI (p = 0.0007 for comparison 
of peak levels). Infection of the marrow-derived CD34+ 
cells at an MOI of 10 produced peak mean copies of total 
viral DNA relative to the single copy gene in the range of 
3–7 copies, and with no consistent change upon addition 
of cytokines (Fig. 3b). In permissive 293T cells peak mean 
copies of total viral DNA relative to single copy gene were 
approximately 10 copies. Tests of infections carried out 
in the presence of the RT inhibitor NVP revealed unde-
tectable levels of viral DNA, again confirming that the 
DNA being detected was due to true infection and were 
not attributable to contaminating plasmid DNA present 
in the virus preparations.
Analysis of circular viral DNAs containing the 2-LTR 
junction sequence revealed only very low levels of cir-
cular DNA in the CD34+ cells (Fig. 3b). Infection of the 
marrow-derived CD34+ cells at an MOI of 10 produced 
peak mean levels of 2-LTR circles in the range of 0.03–
0.07 copies relative to the single copy gene. Thus across 
the various conditions, levels of 2-LTR circular DNAs in 
CD34+ cells were below the levels of total viral DNA by 
approximately 100 fold, whereas in permissive cells the 
2-LTR circle levels were only about tenfold lower than 
the total viral DNA levels. This indicates a strong block 
in infection of marrow derived CD34+ cells even at high 
MOIs, likely at the stage of nuclear entry.
Analysis of the copy numbers of the integrated proviral 
DNA in the CD34+ cells revealed a similar reduction as 
seen in 2-LTR circles (Fig. 3b). We could not detect any 
amplified products in the CD34+ cells after 50 cycles 
of PCR in the cells not exposed to cytokines. Incuba-
tion with cytokines allowed formation of integrated 
DNA at copy numbers in the range of 0.02–0.06 relative 
to the single-copy standard. These levels were similar to 
those seen for 2-LTR circles when cells were exposed 
to cytokines individually or combined, suggesting that 
there is no specific block to integration once the DNAs 
have entered the nucleus in cytokine treated cells; the 
major block is probably at nuclear entry, and the small 
amount that is able to enter the nucleus can continue on 
to integrate.
Circular and integrated lentiviral DNA forms are reduced 
in primary adult human peripheral mobilized CD34+ cells
We performed similar assays for viral DNA levels formed 
upon infection of primary adult human peripheral mobi-
lized CD34+ cells. In general, the findings were simi-
lar to those obtained in the bone marrow-derived cells. 
Infection of the mobilized CD34+ cells at MOI of 1 pro-
duced moderately high levels of total viral DNA (Fig. 4a); 
only very low levels of circular viral DNA containing the 
2-LTR junction (Fig. 4a); and undetectable or extremely 
low levels of integrated proviral DNA (Fig. 4a). Infections 
at higher MOI of 10 again produced substantial levels of 
total viral DNA (Fig. 4b), but only low levels of circular 
or integrated viral DNAs (Fig.  4b). The data reveal that 
the incubation of the mobilized cells with the complete 
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cocktail of cytokines led to a dramatic loss of the total 
viral DNA at the 48 and 72  h time points, especially 
apparent with infection at low multiplicity (Fig. 4a). The 
basis for this loss is unclear.
Increasing amounts of pseudotyped HIV‑1 vector improve 
transduction efficiency but cannot completely overcome 
the block
Primary human bone marrow derived and adult periph-
eral mobilized CD34+ cells were exposed to increasing 
amounts of pseudotyped HIV-1 vector and the resulting 
efficiency of transduction was assessed by flow cytometry 
evaluation of ZsGreen expression. When adult bone mar-
row derived CD34+ cells were exposed to increasing viral 
MOIs between 0 and 10, the numbers of transduced cells 
increased but quickly leveled off with a maximum level of 
about 5–10 % (Fig. 5a). Increasing the viral MOI through 
the range of 0–100 gave some increase in the number 
of cells expressing ZsGreen, but the values plateaued 
at about 5  % green at an MOI of about 10 and failed to 
* * * * * * * * *
* * * * * * * * *
a
b
Fig. 4 The kinetics of production of total viral DNA, 2-LTR circles, and integrated DNAs in adult human peripheral mobilized CD34+ cells after 
exposure to pseudotyped HIV-1 vector at MOI of 1 and 10. Primary human CD34+ cells were incubated with either nevirapine (NVP) or with no 
cytokines (no cyt), Flt3 ligand (FLT3L), stem cell factor (SCF), Thrombopoietin (TPO), or all three cytokines (FST). 293T cells were similarly infected as a 
permissive cell control (293T). Cells were lysed at 12, 24, or 48, and 72 h after infection at MOI of 1, and DNA was extracted and analyzed by taqman 
PCR analysis for products relative to RNase-P (n = 3 per condition and per time point). a DNA levels relative to RNase-P with bars representing mean 
and error bars indicating SEM. b Cells were analyzed at 12, 24, 48 and 72 h after infection at MOI of 10. Results are shown relative to RNase-P with 
bars representing mean and error bars indicating SEM. Asterisk indicates undetectable levels with NVP after amplification for 50 cycles
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increase with further increases in virus. There was a 
drop in number of ZsGreen expressing cells at MOI > 60 
(Fig.  5b). When adult peripheral mobilized CD34+ cells 
were exposed to increasing MOI in the range of 0–10, the 
number of transduced cells increased steadily up to about 
10 % positive (Fig. 5c). At higher MOIs, through the range 
of 0–100, the fraction of positive cells reached a plateau 
value of about 20 % at an MOI of 20 and failed to increase 
with further increases in amount of virus (Fig. 5d).
Discussion
In murine stem cells (MSCs) the major point of restric-
tion for retroviruses is post-integration and is mediated 
by proviral silencing [37–39]. In MSCs, following ret-
roviral integration in the host DNA, specific sequence 
elements of the proviral DNA are recognized by several 
DNA-binding proteins, resulting in assembly of a silenc-
ing complex that permanently silences expression of ret-
roviral genes [31–33, 40–42]. Here we show that in adult 
a b
c d
Fig. 5 Increasing amounts of pseudotyped HIV-1 vector improve transduction efficiency but cannot completely overcome block. Primary human 
bone marrow derived and adult peripheral mobilized CD34+ cells were pre-incubated with Flt3 ligand, stem cell factor, and thrombopoietin for 
24 h and then exposed to various amounts of virus. a Adult bone marrow derived CD34+ cells were exposed to virus at MOI through the range of 
0–10 and evaluated by flow cytometry for expression of ZsGreen after 72 h with mean values and error bars indicating SEM (n = 3). b Adult bone 
marrow derived CD34+ cells were exposed to virus at MOI through the range of 0–100 and evaluated by flow cytometry for expression of ZsGreen 
after 72 h with mean values and error bars indicating SEM (n = 4). c Adult peripheral mobilized CD34+ cells were exposed to virus at MOI through 
the range of 0–10 and evaluated by flow cytometry for expression of ZsGreen after 72 h with mean values and error bars indicating SEM (n = 3). d 
Adult peripheral mobilized CD34+ cells were exposed to virus at MOI through the range of 0–100 and evaluated by flow cytometry for expression 
of ZsGreen after 72 h with mean values and error bars indicating SEM (n = 3)
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human CD34+ HSPCs, transduction is blocked at a dif-
ferent step. Total intracellular viral DNAs were formed 
efficiently, at levels equal to or even above those seen in 
293T cells (Figs. 3, 4). The levels of viral DNA were too 
low for analysis of the sequences at the viral DNA ter-
mini, and thus we cannot rule out the possibility that the 
linear viral DNAs were not full-length and integration-
competent. The major block, however, was seen in the 
appearance of the nuclear DNA forms. The production 
of 2-LTR circles and integrated DNA was consistently 
found to be profoundly reduced in CD34+ cells, to levels 
approximately 1 % of those seen in permissive 293T cells. 
Thus, even at high MOI, formation of circles and provi-
ral DNAs was very low in CD34+ cells. The significant 
reduction in production of 2-LTR circles and integrated 
DNA suggest that HIV-1 is restricted prior to integra-
tion in primary cord CD34+ cells and most likely prior 
to nuclear entry. The block was consistently observed in 
multiple independent preparations of CD34+ HSPCs 
obtained from multiple donors, suggesting that this is a 
very general property of these cells and not highly vari-
able from individual to individual. The block in the adult 
cells is similar to that seen in primary cord-derived 
human CD34+ HSPCs [43], suggesting that restric-
tion prior to integration is a common feature shared by 
hematopoietic stem cells at all developmental stages.
A close examination of our data would support the 
idea that there may be multiple points of pre-integration 
restriction. There is a modest reduction in viral DNA 
synthesis compared to fully permissive cells. Restric-
tion factors such as Trex1, which degrades RT products, 
SAMHD1, which depletes NTPs and may degrade viral 
RNA, and APOBEC3G, which deaminates cytidines and 
may also block reverse transcription, could all contrib-
ute to this restriction. But the more significant point of 
restriction occurs after viral DNA synthesis, at the time 
of nuclear entry of the DNA, as evidenced by the low lev-
els of 2-LTR circles relative to permissive 293T cells. This 
is similar to what we observed in human cord-derived 
HSPCs. It does not appear that there is restriction at the 
time of integration per se, as the proviral DNA levels 
are generally not significantly reduced below that of the 
2-LTR circles. The ratio of 2-LTR circles in CD34+ cells 
to integrated DNA was similar to that of permissive 293T 
cells, suggesting that there was not a significant intranu-
clear block as has been demonstrated in quiescent CD4+ 
cells [44].
Our work also shows that just increasing viral MOI 
does not fully allow this restriction to be bypassed. 
Although modest increases in viral exposure enhance the 
ability to transduce cells it is still only a minority of cells 
that are successfully transduced even when high viral 
MOIs are used. Our current work does not allow us to 
determine whether this plateau is evidence of different 
permissiveness of subpopulations of CD34+ cells with 
regard to lentiviral restriction. A MOI of 10–20 resulted 
in peak transduction and we observed diminished trans-
duction efficiency when MOIs  >  60 of our preparations 
were used. Some components of our preparations, such 
as the VSV G envelope protein, may be inhibitory or toxic 
to the cells. The highly purified preparations currently 
being used in gene therapy trials may achieve higher 
transduction percentages that are adequate for therapy of 
some diseases. The use of very high viral MOIs partially 
overcomes the problem, but better understanding the 
basic biology may eventually offer alternative solutions.
We did not detect a significant block before reverse 
transcription, as would be expected if our use of the 
VSV-G envelope in our pseudotyped virions were signifi-
cantly limiting cellular entry [45]. The high levels of total 
DNA also would not support the idea that the restric-
tion we are observing is due to a limitation at the level 
of cellular entry from an endocytosis defect as has been 
described in resting CD4+ T cells [46]. Total DNA levels 
were modestly lower at MOIs of both 1 and 10 for both 
peripheral mobilized and bone marrow derived CD34+ 
cells, consistent with prior work, but this was not of the 
same magnitude as the 20–400 fold decrease that we 
observed in 2-LTR circles compared to total DNA [47].
We did not see a dramatic improvement in transduc-
tion efficiencies, or in formation of circular or inte-
grated DNAs, with preincubation of the cells with any 
of three cytokines, either individually or all together. 
There were modest increases in transduction, and the 
largest increases were often with a cocktail of all three 
(e.g. Figs.  1d, 2d). The addition of at least one cytokine 
was necessary for the detection of any integrated DNA 
at all in marrow-derived (Fig. 3b) or mobilized (Fig. 4b) 
CD34+ cells, but even with cytokines the levels were still 
very low. Surprisingly, the addition of the combination 
cocktail to the mobilized CD34+ cells led to an unusu-
ally rapid loss of the total viral DNA at 48 and 72 h time 
points (Fig. 4a). The basis for this loss is unclear but sug-
gests that transduction in these cells will not tolerate long 
pre-incubation with cytokines. New culture conditions 
or other modulators of infection are clearly needed to 
improve transduction efficiency in these cells.
Conclusions
HSPCs manifest a strong block to lentiviral infection 
after viral DNA synthesis and before the appearance of 
the nuclear DNA forms. While our investigation reveals 
a strong block prior to appearance of nuclear DNA forms 
our experiments do not rule out the additional possibil-
ity of post-integration silencing in these cells. Under-
standing the mechanism behind HSPC’s ability to block 
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HIV-1 based viral vectors may potentially be exploited 
in advancing gene therapy efficiency. It currently 
remains unclear whether the restriction we are observ-
ing in HSPCs is due to a known restriction factor, a novel 
restriction factor, the absence of a required co-factor, 
or an innate immune response. The determination that 
the specific point in the viral lifecycle at which HIV-1 is 
restricted in human HPSCs is at the time of nuclear entry 
is an important step toward uncovering the molecular 
mechanism restricting HIV-1 transduction of HPSCs.
Methods
Source of human cells
We obtained primary adult marrow-derived and periph-
eral mobilized CD34+ cells from AllCells and StemCell 
Technologies (pre-isolated). All replicates were from dif-
ferent batches of mixed donors.
Pseudovirus preparation
A modified pnl4.3 HIV-1-based vector env− vpr− 
nef−with ZsGreen replacing luciferase [48] was pack-
aged using 293T cells with a vesicular stomatitis virus 
glycoprotein (VSV-G) envelope. Culture supernatants 
were harvested, filtered through a 0.45 μm filter, DNase 
treated and then concentrated by ultracentrifugation 
through a 25  % sucrose cushion and resuspended in 
growth medium. Relative viral MOI titer was determined 
through infection of the permissive 293T cell line with 
serial dilutions of the virus preparation.
Measurement of lentiviral lifecycle stage
DNA isolation was performed using Qiagen DNeasy 
DNA isolation kits. We used a modified multicolor ver-
sion of published taqman quantitative polymerase chain 
reaction (Qpcr) protocols to measure reverse transcrip-
tion (RT) products, 2-long terminal repeats (2-LTR) and 
integrated virus (ALU-LTR) replacing mitochondrial 
genes as a reference with human RNase-P [36]. Primers 
and probes used were:
Reverse transcriptase (RT)
Forward primer: 5′‐TGTGTGCCCGTCTGTTGTGT‐3′




2-Long terminal repeat circles (2-LTR)
Forward primer: 5′‐AACTAGGGAACCCACTGCTT 
AAG‐3′




Alu-long terminal repeats (Alu-LTR)
Forward primer: 5′‐AACTAGGGAACCCACTGCTT 
AAG‐3′




RNase-P copy number reference assay with VIC (5′) 
TAMRA Quencher (3′) was obtained from Life Technol-
ogies. Taqman assays were run for 50 cycles to increase 
the level at which we report not detected. Where noted 
in the text and figures that a target was ‘not detected’, 
product was not amplified during the 50 cycles. ‘Not 
detected’ implies values less than 1 × 10−6 DNA copies 
per genome based on the cycle at which RNase-P was 
detected and the possibility that amplification might have 
occurred after the last cycle at cycle 51.
Expression of fluorophore ZsGreen protein was 
assessed using flow cytometry on an LSR-II or Fortessa 
BD Biosciences.
Cytokine stimulations and stem cell culture
Human HPSCs were cultured in serum free media 
(X-VIVO 20), and stimulated with different cytokines, 
SCF, FLT3L, and TPO at 100 ng/ml in each experiment. 
Pre-incubation was performed for 24  h prior to viral 
exposure and cytokines were maintained at these levels 
after viral exposure. Nevirapine was used at 50 μg/ml as a 
control where noted.
Viral infection of cells
Target cells were placed in culture and then exposed to 
specified amount of pseudotyped virus by spinoculation 
at 37°, 2000 X RPM, for 60 min. Virus was left on the cells 
and not washed off during subsequent culturing.
Statistics
Statistical analysis was performed using Prism Software, 
version 6, for Mac (Graphpad Software Inc., La Jolla, CA, 
USA). Data are displayed when appropriate as mean plus 
or minus the standard error of the mean (SEM). Data 
were compared for statistically relevant differences by 
using Student’s t test with two-tailed analysis.
Abbreviations used HSC, HPC, HSPCs, LTR, HIV-1, 
MLV, MSCs, IL-3, IL-6, IL-7, SCF, FLT3L, TPO, MOI, 
siRNA, RT, 2-LTR, Alu-LTR, VSV-G, ZFP809, YY1, Alu, 
pfu, FACS, TRIM5α, SAMHD1, NTPs, APOBEC3G
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